Skip to Main Navigation
Skip to Page Content

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/8682

2,2-bis(Bromomethyl)-1,3-propanediol: Target Organs and Levels of Evidence for TR-452

Toxicology and Carcinogenesis Studies of 2,2-Bis(Bromomethyl)-1,3-Propanediol (FR-1138 ®) (CASRN 3296-90-0) in F344 Rats and B6C3F1 Mice (Feed Studies)

Chemical (Study Title)
CASRN		 Peer Review Date Route/Exposure Levels Study Laboratory
2,2-bis(Bromomethyl)-1,3-propanediol
3296-90-0		 11/29/1994 Dosed-Feed
R: 0, 2500, 5000, OR 10000 PPM; STOP STUDY: MALES 20000 PPM; 70/GROUP M: 0, 312, 625, OR 1250 PPM; 60/GROUP		 Southern Research Institute

Levels of Evidence

Male Rats: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Skin: SQUAMOUS CELL PAPILLOMA 1/51 0/53 2/51 5/55 11/60 OR KERATOACANTHOMA 3/51 5/53 11/51 16/55 10/60 OR TRICHOEPITHELIOMA 0/51 0/53 0/51 1/55 1/60 OR BASAL CELL ADENOMA 0/51 1/53 0/51 3/55 6/60 OR BASAL CELL CARCINOMA 0/51 0/53 2/51 2/55 0/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 0/51 0/55 1/60 COMBINED 4/51 6/53 14/51 24/55 21/60
  • Subcutaneous Tissue: FIBROMA 2/51 8/53 11/51 15/55 7/60 OR FIBROSARCOMA 0/51 1/53 0/51 0/55 1/60 OR SARCOMA 0/51 0/53 2/51 3/55 2/60 COMBINED 2/51 9/53 13/51 16/55 10/60
  • Mammary Gland: FIBROADENOMA 0/51 4/53 6/51 6/55 5/60 OR ADENOMA 0/51 0/53 1/51 1/55 0/60 COMBINED 0/51 4/53 7/51 7/55 5/60
  • Zymbal Gland: ADENOMA 0/51 0/53 1/51 3/55 2/60 OR CARCINOMA 2/51 1/53 3/51 2/55 15/60 COMBINED 2/51 1/53 4/51 5/55 15/60
  • Oral Cavity: SQUAMOUS CELL PAPILLOMA 0/51 4/53 8/51 10/55 12/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 1/51 0/55 2/60 COMBINED 0/51 4/53 9/51 10/55 13/60
  • Esophagus: SQUAMOUS CELL PAPILLOMA 0/51 0/53 1/51 5/55 0/60
  • Forestomach: SQUAMOUS CELL PAPILLOMA 0/51 0/53 0/51 1/55 5/60
  • Intestines: ADENOMA 0/51 0/53 3/51 4/51 11/55 OR CARCINOMA 0/51 0/53 0/51 2/51 6/55 COMBINED 0/51 0/53 3/51 6/51 15/55
  • Mesothelium (Abdominal Cavity/Tunica Vaginalis): MESOTHELIOMA 0/51 3/53 8/51 9/55 26/60
  • Urinary Bladder: TRANSITIONAL CELL PAPILLOMA 0/51 0/53 1/51 2/55 1/59 OR TRANSITIONAL CELL CARCINOMA 0/51 0/53 0/51 1/55 1/59 COMBINED 0/51 0/53 1/51 3/55 2/59
  • Lung: ALVEOLAR/BRONCHIOLAR ADENOMA 1/51 0/53 3/51 1/55 4/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/51 1/53 0/51 3/55 3/60 COMBINED 1/51 1/53 3/51 4/55 7/60
  • Thyroid Gland Follicular Cell: ADENOMA 0/51 1/53 2/51 2/55 7/59 OR CARCINOMA 0/51 1/53 4/51 1/55 2/59 COMBINED 0/51 2/53 6/51 3/55 9/59
  • Seminal Vesicle: ADENOMA 0/51 0/53 0/51 0/55 1/59 OR CARCINOMA 0/51 0/53 0/51 0/55 1/59 COMBINED 0/51 0/53 0/51 0/55 2/59
  • Hematopoietic System: MONONUCLEAR CELL LEUKEMIA 27/51 29/53 40/51 34/55 25/60
May Have Been Related
  • Kidney Tubular Cell: ADENOMA 0/51 0/53 1/51 3/55 1/59
  • Pancreas Acinar Cell: ADENOMA 1/51 2/53 4/51 3/53 3/59
Non-Neoplastic Lesions
  • KIDNEY: FOCAL ATROPHY; PAPILLARY DEGENERATION; PAPILLARY EPITHELIAL HYPERPLASIA; PELVIS, TRANSITIONAL EPITHELIUM, HYPERPLASIA
  • LUNG: ALVEOLAR/BRONCHIOLAR HYPERPLASIA
  • THYROID GLAND: FOLLICULAR CELL HYPERPLASIA
  • SEMINAL VESICLE: HYPERPLASIA
  • PANCREAS: FOCAL HYPERPLASIA
  • FORESTOMACH: MUCOSAL HYPERPLASIA
  • URINARY BLADDER: HYPERPLASIA
Female Rats: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Oral Cavity: SQUAMOUS CELL PAPILLOMA 2/50 2/51 4/53 5/52 OR SQUAMOUS CELL CARCINOMA 0/50 1/51 1/53 1/52 COMBINED 2/50 3/51 5/53 6/52
  • Esophagus: SQUAMOUS CELL PAPILLOMA 0/50 0/51 1/53 10/52
  • Mammary Gland: FIBROADENOMA 25/50 45/51 46/53 45/52
  • Thyroid Gland Follicular Cell: ADENOMA 0/50 0/51 2/53 3/52 OR CARCINOMA 0/50 0/51 0/53 1/52 COMBINED 0/50 0/51 2/53 4/52
Non-Neoplastic Lesions
  • KIDNEY: FOCAL ATROPHY; PAPILLARY DEGENERATION; PAPILLARY EPITHELIAL HYPERPLASIA
Male Mice: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Harderian Gland: ADENOMA 3/50 6/51 12/50 18/49 OR CARCINOMA 1/50 1/51 4/50 4/49 COMBINED 4/50 7/51 16/50 22/49
  • Lung: ALVEOLAR/BRONCHIOLAR ADENOMA 12/50 4/51 12/50 21/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 3/50 7/51 8/50 11/49 COMBINED 15/50 11/51 16/50 25/49
  • Kidney Tubular Cell: ADENOMA 0/50 0/51 3/50 2/49
May Have Been Related
  • Forestomach: SQUAMOUS CELL PAPILLOMA 0/50 3/51 2/50 2/49 OR SQUAMOUS CELL CARCINOMA 0/50 0/51 1/50 2/49 COMBINED 0/50 3/51 3/50 4/49
Female Mice: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Harderian Gland: ADENOMA 2/52 6/50 8/51 15/50 OR CARCINOMA 1/52 6/50 5/51 7/50 COMBINED 3/52 12/50 13/51 19/50
  • Lung: ALVEOLAR/BRONCHIOLAR ADENOMA 3/52 3/50 9/51 17/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/52 2/50 6/51 5/50 COMBINED 5/52 5/50 15/51 19/50
  • Subcutaneous Tissue: SARCOMA 0/52 1/50 4/51 11/50
May Have Been Related
  • Mammary Gland: CARCINOMA 0/52 0/50 1/51 2/50
  • Forestomach: SQUAMOUS CELL PAPILLOMA 0/52 1/50 5/51 3/50
  • Vascular System (Unspecified): HEMANGIOMA AND HEMANGIOSARCOMA 1/52 2/50 0/51 5/50
Non-Neoplastic Lesions
  • LUNG: ALVEOLAR EPITHELIAL HYPERPLASIA


Chemical (Study Title)
CASRN		 Peer Review Date Route/Exposure Levels Study Laboratory
2,2-bis(Bromomethyl)-1,3-propanediol
3296-90-0		 Dosed-Feed
R: 0,1250,20000, M: 0,625,10000 PPM/5 PER GROUP		 American Biogenics Corp (Bioassay Systems)

Levels of Evidence: None